Navigation Links
Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies
Date:10/24/2007

Enrollment temporarily suspended until approval of amendments, which may

include adjustments in dosing for certain subpopulations

TOKYO, Japan and INDIANAPOLIS, Oct. 24 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) today announced that enrollment of new patients and administration of the study drug in two small prasugrel-related pharmacodynamic clinical trials are being suspended until protocol amendments can be completed and approved. The amendments are due to preliminary results from pharmacokinetic analyses, including patients and healthy subjects/volunteers, indicating that a dose adjustment may be appropriate for certain subpopulations.

These protocol amendments should not be interpreted to represent the outcome of the overall prasugrel clinical development program.

The two small Phase II pharmacodynamic studies compare the levels of inhibition of platelet aggregation (IPA) in patients with coronary artery disease taking the investigational antiplatelet agent prasugrel or clopidogrel (Plavix(R)). Neither study has an efficacy endpoint. Patient enrollment will resume as soon as additional analyses of pharmacokinetic and clinical data are completed, and the protocols are amended and approved by institutional review boards.

"We are suspending enrollment in these two small pharmacodynamic trials so that we can amend current protocols," said J. Anthony Ware, M.D., Lilly cardiovascular platform leader for prasugrel. "These amendments are strictly protocol-related and do not provide a basis for inferring overall outcomes of other prasugrel trials."

Cardiovascular disease is the leading cause of death in the U.S. and wor
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... MOUNT PROSPECT, Ill. , May 21, 2013 /PRNewswire-USNewswire/ ... Domain (gTLD) approval process, the National Association of Boards ... own and operate the .PHARMACY domain suffix has passed ... initial evaluation. NABP intends to launch the .PHARMACY gTLD ... new domain available to legitimate online pharmacies and related ...
(Date:5/21/2013)... Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: ... solution provider and operator of the largest network of ... parent of Chang,an Hospital, today reported its unaudited consolidated ... 2013 [1] . First Quarter 2013 Highlights ... revenues generated from the network business and hospital business, ...
(Date:5/21/2013)... , May 21, 2013  NxStage Medical, Inc. (Nasdaq: ... dialysis products, today announced that it has entered into ... and in-center products to DaVita, the kidney care division ... ) For the use of products ... , NxStage has executed a second amended and ...
Breaking Medicine Technology:NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3Concord Medical Reports First Quarter 2013 Financial Results 2Concord Medical Reports First Quarter 2013 Financial Results 3Concord Medical Reports First Quarter 2013 Financial Results 4Concord Medical Reports First Quarter 2013 Financial Results 5Concord Medical Reports First Quarter 2013 Financial Results 6Concord Medical Reports First Quarter 2013 Financial Results 7Concord Medical Reports First Quarter 2013 Financial Results 8Concord Medical Reports First Quarter 2013 Financial Results 9Concord Medical Reports First Quarter 2013 Financial Results 10Concord Medical Reports First Quarter 2013 Financial Results 11Concord Medical Reports First Quarter 2013 Financial Results 12Concord Medical Reports First Quarter 2013 Financial Results 13NxStage Announces New Agreements with DaVita 2
... 2012  Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company ... technologies in the field of transplantation therapy for patients ... technology from Yale University. "In the ... Herold and his colleagues at Yale University School of ...
... /PRNewswire-iReach/ -- PharmacyGPO, Inc.,  a ... the United States, today announced a three-year agreement ... (Photo: http://photos.prnewswire.com/prnh/20120507/CG01217 ) ... Smith, a leading national wholesaler, will be the ...
Cached Medicine Technology:Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 3
(Date:5/21/2013)... results from SOURCE XT one of the largest, ... reported today at EuroPCR 2013 show good clinical outcomes ... success for all access approaches, valve sizes and delivery ... 2688 consecutively enrolled patients (mean age 81.5 years) undergoing ... centres in 17 countries between July 2010 and October ...
(Date:5/21/2013)... 2013, Paris, France: The Orsiro stent, which is ... biodegradable polymer, demonstrated non-inferiority to the Xience Prime ... in-stent late lumen loss at nine months in ... EuroPCR 2013 today. , The BIOFLOW-II substudy used ... to quantitatively assess neointimal hyperplasia and stent apposition ...
(Date:5/21/2013)... 21, 2013 Arizona State University ... want to develop their ideas into solutions, products ... , The university is recruiting participants for AREA48 ... space” that provides early-stage entrepreneurs with opportunities to ... open to anyone, ASU is particularly seeking participation ...
(Date:5/21/2013)... 21, 2013 According to a May 13, ... Use of Botox,” Botox injections have become the ... in 2002 (Go to goo.gl/8iYbD). Although it is mostly associated ... men. The injection makes facial wrinkles less visible by paralyzing ... for about three months. This means that people who are ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Wright Conserve hip replacement lawsuits in ... an Order in response to a request from Plaintiffs’ ... of the Defendant. The May 17th Order grants ... interviews may be conducted. (In re: Wright Medical Technology, ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
... guinea worm disease is almost eradicated from the planet earth. ... could be exterminated in a couple of years from now. ... ,Currently around 25,000 people in nine countries across the ... million people in twenty countries in the early 1980s. ...
... performance is reported to be the latest trend which is ... keen to learn and develop their skills to make sure ... interest of patients. ,More than 170 physician ... emergency care through the Physician Consortium for Performance Improvement organized ...
... cancers of the “triple negative” type are destructive and lethal, ... to a novel// study Published in the May 1, 2007 ... these tumors occur commonly among women who are African American ... the lower socioeconomic status (SES). The study also showed that ...
... children suffering ADHD are prone to alcohol addiction in ... suggesting that alcohol related problems could begin around the ... family stress appear to add to the risk of ... that children with attention deficit hyperactivity disorder (ADHD) are ...
... the incidence of chicken pox cases is on the rise. ... especially in the southern districts, are gearing up to tackle ... would be the first casualty if chicken pox is not ... cases have been already reported in a rather serious condition ...
... Going in for angioplasty? Pause for a moment. It has now ... arteries//. ,So much so, more than half a ... or premature angioplasty, suggests a new study. ,More important, ... heart patients, it says. ,Dr William Boden of ...
Cached Medicine News:Health News:'Triple Negative' Breast Cancers Seem to Affect the Young, Minority 2Health News:ADHD Problem in Children – a Risk Factor for Alcohol Problems in Later Lif 2Health News:ADHD Problem in Children – a Risk Factor for Alcohol Problems in Later Lif 3
Alphabetically organized monographs on more than 1,000 generic and 3,000 trade name drugs....
... Drug Companion is a comprehensive, authoritative ... 5,500 entries, with overdose management, Canadian ... This "Mini-Suite" of drug references and ... the PEPID Suites (ED, PRIMARY CARE ...
... Pocket Drug Guide 2005 includes over 1,000 ... relating to their selection and administration. Organized ... drug includes key data featuring common uses ... implications and patient education information. A list ...
... A to Z Drug Facts ... detailed information on thousands of medications. ... contraindications, side effect, drug interactions, patient ... ideal drug reference for physicians, students, ...
Medicine Products: